
****

**Symposium programme:**

**“Therapeutic vaccination and host-directed (immuno) therapy against TB”**

**Tuesday afternoon 30th January 2018**

**Programme**

14.00 - 14.05 Opening and Welcome - Nick Drager, TBVI, the Netherlands. [Presentation Nick Drager](http://www.tbvi.eu/wp-content/uploads/2018/02/TBVI-Diablerets-2018-final_ND.pptx)

*Chair:* Frank Verreck (BPRC, the Netherlands)

14.05 – 14.30 Introductory and overarching overview- Stefan Kaufmann, MPIIB, Germany

[Presentation Stefan Kaufmann](http://www.tbvi.eu/wp-content/uploads/2018/02/TBVAC-TBVI-Les-Diablerets-Jan-Feb2018_SK.pp)

14.30 – 15.00 *Exploring host-pathogen interactions for host directed therapies -* Dr. Ulrich Schaible, Research Centre Borstel, Borstel, Germany [Presentation Ulrich Schaible](http://www.tbvi.eu/wp-content/uploads/2018/02/TBVI_Schaible_short.pdf).

15.00 – 15.30 *Evaluation of host-directed therapies against TB in the macaque model* - Dr. Deepak Kaushal, Tulane NHP Research Centre (TNPRC), Covington, United States

15.30 – 16.00 *A perspective on therapeutic vaccination from the TB drug development space -*

Prof. Eric Nuermberger, Johns Hopkins University, Baltimore, United States

16.00 – 16.30 Coffee break / snack

16.30 – 17.00 *Strategies for clinical development of therapeutic vaccines for DR-TB -* Prof. Dr. Mark Hatherill, South African Tuberculosis Initiative, University of Cape Town, South Africa [Presentation Mark Hatherill](http://www.tbvi.eu/wp-content/uploads/2018/02/Diableret2018_Hatherill_FINAL.pptx)

17.00 – 17.30 *Therapeutic vaccines in HIV infection: challenges and future* - Prof. Dr. Giuseppe Pantaleo, Swiss Vaccine Research Institute, CHUV, Lausanne, Switzerland

17.30 – 18.00 *Developing biomarkers into products: An overview -* Bill Rodriguez, Draper Richards Kaplan Foundation, Boston, United States. [Presentation Bill Rodriguez](http://www.tbvi.eu/wp-content/uploads/2018/02/Rodriguez_TBVI_30-January_Web.pptx)

18.00 – 19.00 Final session: EDCTP-supported new TB vaccine clinical projects

*Chair: Ole Olesen – EDCTP, the Netherlands.* [Presentatie Ole Olesen](http://www.tbvi.eu/wp-content/uploads/2018/02/TBVI-presentation_OO.ppt)

18.00 - 18.05 *Introduction* – Hannu Laang, EC, Belgium [Presentatie Hannu Laang](http://www.tbvi.eu/wp-content/uploads/2018/02/LesDiablerets-2018-HL.pptx)

18.05 – 18.20 *A multicenter phase III clinical trial with VPM1002* - Leander Grode, VPM, Germany

18.20 – 18.35 *MTBVAC in newborns, a phase 2a clinical trial* - Ingrid Murillo, Biofabri, Spain

[Presentatie Ingrid Murillo](http://www.tbvi.eu/wp-content/uploads/2018/02/Les-Diablerets-Meeting-29-Jan-1-Feb-2018_Biofabri_Cora.pptx)

18.35 – 18.50 *Prevention of recurrent TB disease consortium, a phase 2a trial (H56:IC31)* - Morten Ruhwald, SSI), Denmark

18.50 - 19.05 *A clinical trial to demonstrate the safety and efficacy of H56:IC31 for the prevention of tuberculosis infection* - Ann Ginsberg, Aeras, United States [Presentatie Ann Ginsberg](http://www.tbvi.eu/wp-content/uploads/2018/02/POI-Les-Diabelerets_2018-Ginsberg.pptx)

19.15 – 20.00 *Reception (Eurotel)*

20.00 *Dinner - Restaurant Eurotel*